Revolution Medicines/RVMD
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Ticker
RVMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Redwood City, United States
Employees
411
Website
www.revmed.com
RVMD Metrics
BasicAdvanced
$6.2B
Market cap
-
P/E ratio
-$3.71
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$6.2B
Beta
1.46
Financial strength
Current ratio
18.45
Quick ratio
18.176
Long term debt to equity
4.628
Total debt to equity
5.102
Interest coverage (TTM)
-1,740.55%
Management effectiveness
Return on assets (TTM)
-22.11%
Return on equity (TTM)
-36.17%
Valuation
Price to revenue (TTM)
1,069.37
Price to book
3.57
Price to tangible book (TTM)
3.73
Price to free cash flow (TTM)
-10.66
Growth
Revenue change (TTM)
-86.89%
Earnings per share change (TTM)
22.83%
3-year revenue growth
-52.11%
3-year earnings per share growth
24.32%
What the Analysts think about RVMD
Analyst Ratings
Majority rating from 13 analysts.
RVMD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$116M
-28.17%
Profit margin
0.00%
-100.00%
RVMD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.92
-$0.99
-$1.14
-$0.70
-
Expected
-$0.82
-$1.01
-$0.88
-$0.75
-$0.75
Surprise
11.68%
-1.29%
29.24%
-6.18%
-
RVMD News
AllArticlesVideos
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
GlobeNewsWire·2 months ago
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $6.2B as of July 04, 2024.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of July 04, 2024.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Revolution Medicines stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.